Project Grant HT94252410472
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$519K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...
The federal Project Grant award of $1,715,075.00 was provided by the Defense Health Agency to Beth Israel Deaconess Medical Center, Inc. (Bidmc) under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research on "The Role of TBI Derived DAMPS in Bacterial Pneumonia" over a period from September 30, 2023 to September 29, 2026. As a major academic medical center and teaching hospital, Bidmc has an extensive portfolio of federal grants and...
The Department of the Army Medical Command awarded Beth Israel Deaconess Medical Center, Inc. (BIDMC) a $1.3 million Project Grant over four years from July 2021 to June 2025 under the Military Medical Research and Development program (CFDA 12.420). The grant will fund BIDMC's research project "BH3 MIMETIC DRUGS FOR PROSTATE CANCER THERAPY." Through this funding, BIDMC researchers will investigate medical solutions for prostate cancer by developing BH3 mimetic drugs to transform...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...
This $1,994,937 federal Project Grant award, funded by the U.S. Department of Defense through the Military Medical Research and Development program (CFDA 12.420), is supporting research to confirm the effectiveness of acupuncture in treating the symptoms of Gulf War Illness. The grant recipient, Beth Israel Deaconess Medical Center, Inc. (Bidmc), a prominent academic medical center in Boston, will conduct this research project over a 4-year period from August 2024 to July 2028. Bidmc has...
This $1,723,552 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to target specific long non-coding RNAs (lncRNAs) in novel combined therapies. The goal is to modulate the TSP1-dependent immune microenvironment vulnerabilities in advanced thyroid cancer. The grant has a performance period from September 1, 2025 to...
This $345,800 Project Grant was awarded on May 1, 2024 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The grant supports research on the "Role of Stress Granules in the Pathogenesis and Therapy of Pulmonary Hypertension", with a performance period from May 1, 2024 to April 30, 2026. The Military Medical Research and Development program funds a...
This $2,136,000.00 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program supports advanced biomedical research at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The funding will be used to conduct research on "Reversibility and Therapeutic Targeting of Treatment-Emergent Neuroendocrine Prostate Cancer" over a 3-year period from May 1, 2025 to April 30, 2028. As a...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
The federal Project Grant award, valued at $3,062,579.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports an integrated approach to identifying biopsychosocial aspects of pain in fibrous dysplasia/McCune-Albright syndrome, a rare genetic bone disorder, at Boston Children's Hospital, a non-profit pediatric medical research institution. The research aims to transform healthcare for military service members...